Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy and Safety of Neu2000KWL in Patients Who Resuscitated After Out-of-hospital Cardiac Arrest Patient and Receiving Therapeutic Hypothermia

Trial Profile

A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy and Safety of Neu2000KWL in Patients Who Resuscitated After Out-of-hospital Cardiac Arrest Patient and Receiving Therapeutic Hypothermia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelonemdaz (Primary)
  • Indications Heart arrest
  • Focus Therapeutic Use
  • Acronyms AWAKE
  • Sponsors GNT Pharma

Most Recent Events

  • 02 Sep 2024 Primary endpoint () has not been met, according to Results presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
  • 02 Sep 2024 Results (n=105) assessing efficacy and safety of nelonemdaz for patients with out-of-hospital cardiac arrest, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology.
  • 23 Jul 2022 Trial design published in the Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top